Integra LifeSciences (NASDAQ:IART) Hits New 52-Week High – What’s Next?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $18.30 and last traded at $17.61, with a volume of 2322863 shares trading hands. The stock had previously closed at $17.58.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IART. Truist Financial lowered their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $11.00 to $16.00 in a report on Thursday, May 28th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Thursday, June 18th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Finally, Wall Street Zen raised shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $16.20.

Integra LifeSciences Price Performance

The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -2.74, a PEG ratio of 1.22 and a beta of 1.24. The stock has a 50 day moving average price of $14.40 and a two-hundred day moving average price of $12.41.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. The firm had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.Integra LifeSciences’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IART. Osaic Holdings Inc. grew its stake in Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares in the last quarter. State of Tennessee Department of Treasury raised its position in Integra LifeSciences by 7.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after purchasing an additional 1,964 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after buying an additional 1,975 shares during the period. Capital Fund Management S.A. boosted its stake in shares of Integra LifeSciences by 5.7% in the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock valued at $535,000 after buying an additional 1,997 shares during the period. Finally, Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences during the fourth quarter worth about $25,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.